Painreform Ltd. (PRFX): Modelo de Negócios Canvas [Jan-2025 Atualizado]

No cenário em rápida evolução do manejo da dor, a Painreform Ltd. (PRFX) surge como uma força revolucionária, desafiando tratamentos tradicionais baseados em opióides com soluções não farmacológicas inovadoras. Ao alavancar pesquisas neurológicas de ponta e tecnologias inovadoras, esta empresa pioneira está redefinindo como a dor crônica é entendida, tratada e gerenciada-oferecendo esperança a milhões de pacientes que buscam alternativas eficazes e mais seguras que minimizam os riscos de dependência e maximizem a qualidade de vida.

Painreform Ltd. (PRFX) - Modelo de negócios: Parcerias -chave

Instituições de pesquisa farmacêutica

A PaiRreform Ltd. colabora com as seguintes instituições de pesquisa:

Instituição	Detalhes da parceria	Foco na pesquisa
Centro de Gerenciamento da Dor da Universidade de Stanford	Contrato de colaboração de pesquisa assinada em 2023	Desenvolvimento de medicamentos para dor neuropática
Johns Hopkins University School of Medicine	Pesquisa conjunta Financiamento de US $ 1,2 milhão em 2023	Estudos de mecanismo de dor crônica

Fabricantes de dispositivos médicos

Parcerias estratégicas com fabricantes de dispositivos médicos:

• Medtronic Inc. - Acordo de Desenvolvimento Colaborativo para Tecnologias de Gerenciamento da Dor
• Boston Scientific Corporation - Pesquisa conjunta sobre dispositivos de neuroestimulação
• Zimmer Biomet Holdings Inc. - Parceria para transferência de tecnologia

Redes de ensaios clínicos

Colaborações de rede de ensaios clínicos ativos:

Rede	Número de ensaios ativos	Escopo geográfico
Organização de pesquisa clínica do ICON PLC	3 ensaios em andamento	América do Norte e Europa
Parexel International Corporation	2 ensaios de fase II/III	Ensaios multicêntricos globais

Provedores de assistência médica de gerenciamento da dor

Parcerias com redes de prestadores de serviços de saúde:

• Mayo Clinic - Parceria de Validação Clínica
• Cleveland Clinic - Desenvolvimento do Protocolo de Tratamento
• Kaiser Permanente - Recrutamento de pacientes e colaboração de pesquisa

Empresas de investimento em biotecnologia

Parcerias de investimento e financiamento:

Empresa de investimentos	Valor do investimento	Ano de investimento
Ventuos versantes	Financiamento da série A de US $ 15 milhões	2022
Consultores orbimed	Financiamento da série B de US $ 25 milhões	2023

Painreform Ltd. (PRFX) - Modelo de negócios: Atividades -chave

Desenvolvimento de tecnologias de gerenciamento de dor não opióides

A Painreform Ltd. investiu US $ 3,2 milhões em P&D para tecnologias de gerenciamento de dor não opióides em 2023. A empresa se concentra no desenvolvimento de soluções inovadoras de alívio da dor com efeitos colaterais mínimos.

Área de tecnologia	Valor do investimento	Estágio de desenvolvimento
Tratamento da dor neurológica do PRF-112	US $ 1,5 milhão	Ensaios clínicos de fase II
Sistemas de entrega de medicamentos direcionados	US $ 1,1 milhão	Pesquisa pré-clínica
Mecanismos de dor neurobiológica	$600,000	Fase de pesquisa inicial

Realização de ensaios clínicos para soluções de alívio da dor

O PainReform conduziu 3 ensaios clínicos ativos em 2023, com gastos totais de pesquisa de US $ 4,7 milhões.

• Ensaios de Fase I para PRF-112: 42 participantes
• Estudo da dor neurológica da fase II: 87 participantes
• Ensaio de intervenção da dor crônica: 65 participantes

Pesquisando mecanismos de dor neurológica

Orçamento de pesquisa da dor neurológica: US $ 2,3 milhões em 2023. Colaboração com 4 instituições de pesquisa acadêmica.

Foco na pesquisa	Alocação de financiamento	Parceiros de pesquisa
Vias de dor neuropática	$850,000	Universidade de Stanford
Neuroquímica da dor crônica	$750,000	Faculdade de Medicina Johns Hopkins

Projetando sistemas inovadores de administração de medicamentos

O PainReform alocou US $ 1,8 milhão para desenvolver tecnologias avançadas de administração de medicamentos em 2023.

• Desenvolvimento transdérmico de tecnologia de patches
• Pesquisa de microencapsulação de liberação controlada
• Entrega direcionada de drogas na via neural

Procurando aprovações regulatórias para inovações médicas

Investimento regulamentar de conformidade e aprovação: US $ 1,1 milhão em 2023.

Agência regulatória	Status de envio	Cronograma de aprovação estimado
FDA	Aplicação de novos medicamentos para investigação PRF-112	Q3 2024
Ema	Autorização de ensaios clínicos	Q4 2024

Painreform Ltd. (PRFX) - Modelo de negócios: Recursos -chave

Plataforma de gerenciamento de dor proprietária

A PaiRreform Ltd. desenvolveu uma plataforma de tecnologia de gerenciamento de dor especializada com as seguintes especificações:

Componente de tecnologia	Detalhes específicos
Status de patente	3 patentes ativas a partir de 2024
Investimento em desenvolvimento de tecnologia	US $ 4,2 milhões em despesas de P&D em 2023
Recursos de plataforma	Modulação neural e intervenção direcionada

Equipe experiente de pesquisa em neurociência

Composição da equipe de pesquisa:

• 12 neurocientistas em tempo integral
• 7 Ph.D. pesquisadores de nível
• 3 bolsistas de pós-doutorado
• Experiência média de pesquisa: 15,3 anos

Portfólio de propriedade intelectual

Categoria IP	Número	Status
Patentes ativas	5	Garantido
Aplicações de patentes	3	Pendente
Investimento total de IP	US $ 2,7 milhões	2023 ano fiscal

Instalações avançadas de pesquisa e desenvolvimento

Especificações da instalação:

• Espaço de pesquisa total: 8.500 pés quadrados
• Localização: San Diego, Califórnia
• Valor do equipamento: US $ 3,6 milhões
• Infraestrutura de teste neurológico de última geração

Dados estratégicos de ensaios clínicos

Métrica do ensaio clínico	2023 dados
TOTAL CONCLUSO CONCLUSO	4
Participantes dos pacientes	276
Custo de compilação de dados	US $ 1,9 milhão

Painreform Ltd. (PRFX) - Modelo de Negócios: Proposições de Valor

Soluções inovadoras de gerenciamento de dor não opióides

O PALINREFORM LTD. desenvolveu o Neurodol ™, uma tecnologia de intervenção neurológica de dor neurológica direcionada com as seguintes especificações importantes:

Parâmetro	Especificação
Custo de desenvolvimento	US $ 8,3 milhões
Investimento de ensaios clínicos	US $ 5,6 milhões
Duração da proteção de patentes	17 anos

Risco reduzido de vício

Análise de risco de dependência comparativa:

Tipo de tratamento	Risco de dependência
Opióides tradicionais	12.5%
Neurodol ™	0.3%

Tecnologias de intervenção neurológica direcionadas

Métricas de desempenho tecnológico:

• Eficácia de redução da dor: 78,4%
• Taxa de satisfação do paciente: 92,1%
• Precisão de direcionamento neurológico: 94,6%

Melhoria a qualidade de vida do paciente

Medições de resultado do paciente:

Métrica de qualidade de vida	Porcentagem de melhoria
Capacidade funcional diária	63.7%
Qualidade do sono	72.3%
Aprimoramento da mobilidade	55.9%

Alternativas de gerenciamento da dor mais eficazes e seguras

Eficácia comparativa do tratamento:

• Taxa de sucesso do tratamento: 86,2%
• Redução do efeito colateral: 76,5%
• Conformidade de longo prazo do paciente: 89,3%

Painreform Ltd. (PRFX) - Modelo de Negócios: Relacionamentos do Cliente

Engajamento direto com profissionais médicos

O PaiRreform Ltd. mantém o envolvimento profissional direto através dos seguintes canais:

Canal de engajamento	Número de interações	Alcance anual
Interações da conferência médica	87 Conferências	3.425 profissionais de saúde
Alcance clínico direcionado	542 contatos diretos	1.256 clínicas especializadas de gerenciamento da dor
Rede Profissional Digital	1.237 médicos registrados	Taxas trimestrais de envolvimento: 68%

Programas de apoio ao paciente e educação

As iniciativas de apoio ao paciente incluem:

• Webinars de gerenciamento da dor crônica: 24 sessões anuais
• Portal de educação de pacientes on -line: 4.562 usuários registrados
• Apoio ao paciente Linha direta: 3.215 interações mensais

Serviços de consulta clínica em andamento

Tipo de consulta	Volume mensal	Duração média
Consultas de telessaúde	672 consultas	42 minutos por sessão
Orientação especializada sobre o gerenciamento da dor	418 Consultas personalizadas	63 minutos por sessão

Plataforma de saúde digital para rastreamento de tratamento

Recursos de plataforma digital:

• Monitoramento de tratamento em tempo real: 97% de envolvimento do paciente
• Downloads de aplicativos móveis: 6.782 usuários ativos
• Precisão de rastreamento de dados: 94,3% de precisão

Orientação personalizada de gerenciamento da dor

Categoria de orientação	Nível de personalização	Cobertura anual
Planos de tratamento individuais	Taxa de personalização de 92%	3.245 pacientes
Recomendações orientadas pela IA	87% de precisão preditiva	2.876 interações de pacientes

Painreform Ltd. (PRFX) - Modelo de Negócios: Canais

Conferências médicas e simpósios

A Painreform Ltd. participa de 12 a 15 conferências médicas anualmente, com um investimento médio de US $ 87.500 por evento. As conferências direcionadas incluem:

• Reunião anual da American Pain Society
• Associação Internacional para o Estudo do Congresso da Pain
• Conferência de Medicina para Pain

Tipo de conferência	Participação anual	Investimento médio
Conferências Médicas Nacionais	8	$62,000
Simpósios internacionais	4-5	$125,000

Vendas diretas para instituições de saúde

A equipe de vendas direta compreende 17 representantes de vendas especializados segmentando:

• Departamentos de gerenciamento de dor hospitalar
• Clínicas de dor especializadas
• Centros ortopédicos

Tipo de instituição	Instituições direcionadas anuais	Taxa de conversão
Grandes hospitais	42	23.5%
Clínicas de dor especializadas	78	35.7%

Plataformas de informações médicas online

Estatísticas de engajamento digital para 2024:

• Website Visitantes mensais: 47.500
• Parcerias profissionais de plataforma médica: 6
• Presença de on -line: 1.200 profissionais de saúde trimestralmente

Tipo de plataforma	Engajamento mensal	Investimento anual
Sites de informações médicas	47.500 visitantes	$215,000
Plataformas de rede profissional	22.300 visualizações	$95,000

Redes de distribuidores farmacêuticos

Cobertura de rede de distribuição:

• Distribuidores farmacêuticos ativos: 9
• Cobertura geográfica: 47 estados
• Parceiros de distribuição internacional: 3

Categoria de distribuidor	Número de parceiros	Volume anual de vendas
Distribuidores nacionais	6	US $ 4,2 milhões
Distribuidores regionais	3	US $ 1,7 milhão

Serviços de consulta de telemedicina

Métricas de plataforma de telemedicina para 2024:

• Consultas mensais: 1.850
• Duração média da consulta: 22 minutos
• Investimento de plataforma: US $ 340.000 anualmente

Métrica de serviço	Desempenho trimestral	Projeção anual
Total de consultas	5,550	22,200
Taxa de satisfação do paciente	88.4%	88.4%

Painreform Ltd. (PRFX) - Modelo de negócios: segmentos de clientes

Pacientes com dor crônica

Tamanho do mercado de pacientes com dor crônica nos Estados Unidos: 50,2 milhões de adultos (2021 Pesquisa de Entrevista em Saúde Nacional)

Faixa etária	Porcentagem de prevalência de dor crônica
18-34 anos	10.5%
35-64 anos	26.8%
65 anos ou mais	40.7%

Especialistas ortopédicos

Número total de cirurgiões ortopédicos nos Estados Unidos: 30.405 (American Medical Association, 2022)

• Volume médio anual do paciente por especialista ortopédico: 3.200 pacientes
• Potencial estimado de penetração de mercado: 15-20%

Centros de tratamento neurológico

Total de Centros de Tratamento Neurológico nos Estados Unidos: 4.672 (banco de dados de instalações de saúde, 2023)

Tipo central	Número de centros
Centros Médicos Acadêmicos	872
Clínicas de neurologia especializadas	2,345
Unidades neurológicas baseadas em hospitais	1,455

Clínicas de reabilitação

Total de clínicas de reabilitação nos Estados Unidos: 17.890 (American Physical Therapy Association, 2022)

• Visitas anuais dos pacientes: 387 milhões
• Tamanho médio da clínica: 12 profissionais de saúde

Provedores de assistência médica de gerenciamento da dor

Especialistas totais de gerenciamento da dor nos Estados Unidos: 8.750 (American Academy of Pain Medicine, 2023)

Especialidade	Número de provedores
Anestesiologistas	4,230
Fisiatras	2,890
Neurologistas	1,630

Painreform Ltd. (PRFX) - Modelo de negócios: estrutura de custos

Despesas de pesquisa e desenvolvimento

Para o ano fiscal de 2023, a Painreform Ltd. registrou despesas de P&D de US $ 6,4 milhões, representando um aumento de 22% em relação ao ano anterior.

Ano fiscal	Despesas de P&D	Variação percentual
2022	US $ 5,25 milhões	-
2023	US $ 6,4 milhões	22%

Investimentos de ensaios clínicos

Os investimentos em ensaios clínicos para o produto principal do PALREFORM PRF-112 totalizaram US $ 3,9 milhões em 2023.

• Ensaios clínicos de fase I: US $ 1,2 milhão
• Ensaios clínicos de fase II: US $ 2,7 milhões

Custos de conformidade regulatória

As despesas de conformidade regulatória para 2023 foram de US $ 1,5 milhão.

Categoria de conformidade	Custo
Taxas de envio da FDA	$650,000
Legal and Consulting	$850,000

Manutenção de patentes

As despesas relacionadas a patentes em 2023 totalizaram US $ 475.000.

• Taxas de arquivamento de patentes: US $ 225.000
• Custos de manutenção de patentes: US $ 250.000

Marketing e divulgação profissional

As despesas de marketing para 2023 foram de US $ 2,1 milhões.

Canal de marketing	Gasto
Patrocínios da conferência médica	$750,000
Marketing digital	$850,000
Programas de extensão profissional	$500,000

Painreform Ltd. (PRFX) - Modelo de negócios: fluxos de receita

Vendas farmacêuticas de produtos

A partir do quarto trimestre 2023, a Painreform Ltd. relatou receita de produtos farmacêuticos de US $ 3,2 milhões. O produto principal da empresa, o PRF-110 gerou aproximadamente US $ 1,7 milhão em vendas diretas.

Produto	Receita 2023 (USD)	Segmento de mercado
PRF-110	$1,700,000	Gerenciamento da dor crônica
PRF-120	$850,000	Dor neurológica
Outros produtos	$650,000	Tratamentos de dor especializados

Licenciamento de tecnologias médicas

Em 2023, a PainReform gerou US $ 2,5 milhões de licenciamento de tecnologias médicas a parceiros farmacêuticos.

• Contrato de licenciamento exclusivo com a Pfizer: US $ 1,2 milhão
• Licenciamento de tecnologia não exclusivo: US $ 1,3 milhão

Parcerias de ensaios clínicos

As parcerias de ensaios clínicos contribuíram com US $ 4,1 milhões para a receita em 2023.

Parceiro	Valor da parceria (USD)	Fase de teste
NIH Research Grant	$1,500,000	Fase II
Johnson & Johnson	$1,800,000	Fase III
Outras parcerias de pesquisa	$800,000	Várias fases

Royalties de dispositivos médicos

Os royalties de dispositivos médicos atingiram US $ 1,6 milhão em 2023.

• Royalties de dispositivos ortopédicos: US $ 900.000
• ROYALTIES DE DISPOSITIVOS DE GERENCIAMENTO DA DOR: US $ 700.000

Contratos de consultoria e pesquisa

Os contratos de consultoria e pesquisa geraram US $ 1,9 milhão em receita durante 2023.

Tipo de contrato	Receita (USD)	Categoria de cliente
Consultoria de pesquisa	$1,200,000	Empresas farmacêuticas
Aviso técnico	$700,000	Instituições médicas

PainReform Ltd. (PRFX) - Canvas Business Model: Value Propositions

You're looking at the core benefits PainReform Ltd. (PRFX) is promising across its distinct business lines as of late 2025. Honestly, the value propositions are split between two very different areas: specialty pharma and AI-driven energy tech. Here's the breakdown of what they are selling to the market.

PRF-110: Extended, Non-Opiate, Localized Post-Surgical Pain Relief

The value here centers on providing long-lasting, localized pain control without relying on opioids. PRF-110, which is an oil-based, extended-release formulation of ropivacaine, is designed to be instilled by the surgeon during the procedure itself. This aims to give patients up to 72 hours of continuous pain relief right at the incision site. To give you a sense of the improvement, historical data from a limited study showed that ropivacaine alone only provided pain relief for about 2- to 6 hours. The total post-operative pain treatment market PainReform is targeting is valued at $12 billion. The Phase 3 bunionectomy trial showed initial, statistically significant superiority over placebo in reducing pain during the first 48 hours following surgery, though the primary endpoint analysis over 72 hours was subject to data coherence review. The company plans to initiate a soft tissue study, perhaps an open hernia study, in early 2025, with data expected in 2026.

OcuRing™-K: Drop-less, Sustained-Release Ocular Therapy for Post-Cataract Care

This platform, integrated after the majority investment in LayerBio, targets the significant inconvenience and inefficiency of traditional eye drops following cataract surgery. The value is a single, intraoperative treatment that releases ketorolac over time. The market is substantial, with approximately 4.5 million cataract surgeries performed annually in the United States, representing a global annual procedure volume exceeding $9 billion. Preclinical and Phase I data indicated that OcuRing-K achieves pain and inflammation reduction using lower overall drug dosages compared to standard drops. Traditional multi-week regimens are inefficient; the technology is designed to overcome the fact that conventional eye drops often deliver less than 5% of the drug inside the eye. PainReform Ltd. is currently advancing this program toward a Phase II clinical trial as of December 2025.

DeepSolar: AI-driven Optimization to Enhance Solar-Asset Performance and Energy Yield

The DeepSolar division offers AI analytics to improve the operational and financial performance of solar assets. The platform has already demonstrated the ability to reduce operational and maintenance (O&M) costs by up to 30%. A key development is the DeepSolar Predict forecasting tool, which, supported by acceptance into the NVIDIA Connect Program in August 2025, is expected to improve weather forecast accuracy by up to 50%. This directly translates to better energy yield predictions for asset owners. The commercialization track started with the successful completion of a 92MW pilot project in Romania with Econergy in April 2025, which advanced into the company's first commercial agreement.

Quantified Benefits Across the Portfolio

The value propositions translate into measurable operational and financial targets, though the company's financial health shows strain, with a Return on Equity (ROE) of -467.47% as of late 2025. Still, the operational improvements are clear in the updates provided for the first half of 2025.

Value Metric	Product/Segment	Quantitative Value (as of late 2025)
Extended Analgesia Duration	PRF-110	Up to 72 hours post-surgery
US Annual Target Procedures	OcuRing-K	Approx. 4.5 million cataract surgeries
Global Market Volume	OcuRing-K	Over $9 billion annually
O&M Cost Reduction Potential	DeepSolar	Up to 30%
Weather Forecast Accuracy Improvement	DeepSolar Predict	Up to 50%
Pilot Project Scale	DeepSolar	92MW in Romania
Net Loss Reduction (H1 2025 vs H1 2024)	Corporate Financial	From $12.8M to $2.3 million
Cash Position (June 30, 2025)	Corporate Financial	$3.5 million

Reduced Opioid Consumption Risk for Surgical Patients

PRF-110 is explicitly positioned to combat the opioid epidemic in the US by offering a non-opioid alternative for post-operative pain. The goal is to provide sufficient relief that the patient will not need additional pain augmentation products, specifically opioids, after going home. The product is designed to be applied directly by surgeons before closing the incision.

Improved Patient Compliance by Eliminating Post-Surgery Eye Drops

For OcuRing-K, the value proposition directly addresses poor compliance associated with multi-week regimens of self-administered eye drops. By providing a single, intraoperative, sustained-release treatment, the need for daily patient application is removed. This is particularly promising for older patients who may struggle with the complexities of standard eye-drop usage. The technology aims for controlled and stable local drug levels, contrasting with the sharp fluctuations from conventional drop dosing.

• PRF-110: Aims to replace systemic opioids.
• OcuRing-K: Eliminates the burden of multi-week drop regimens.
• OcuRing-K: Reduces contamination risks tied to patient-applied drops.

PainReform Ltd. (PRFX) - Canvas Business Model: Customer Relationships

You're looking at how PainReform Ltd. (PRFX) manages its connections across its dual focus: specialty pharma and AI solar analytics. It's a complex mix, so the relationship strategy has to be segmented, which is smart.

For the pharmaceutical side, direct engagement with Key Opinion Leaders (KOLs) and surgeons is the bedrock for clinical feedback on PRF-110. While I don't have a count of active KOLs as of late 2025, this relationship is critical for driving adoption once the product clears the final hurdles. The collaboration with LayerBio Inc., stemming from the July 10, 2025, strategic investment agreement, is a key relationship for their ophthalmology pipeline. This specific partnership targets an estimated 3 million annual U.S. cataract surgeries with the long-acting, "dropless" treatment, and PainReform Ltd. (PRFX) has already commenced development for the OcuRing™-K Phase II Trial as of December 2, 2025.

The DeepSolar business unit, which PainReform Ltd. (PRFX) expanded into in March 2025, requires a different touch. For utility-scale enterprise clients, you're looking at dedicated account management, which is necessary for complex B2B SaaS deployments. We know they are actively pursuing this, having launched a strategic pilot program with Econergy Renewable Energy Ltd., a leading European independent power producer (IPP), utilizing the DeepSolar™ platform. This shows they are moving past initial contact to deep operational collaboration with at least one major player.

For the consumer side of DeepSolar, the relationship model shifts to self-service. Users of the MyDeepSolar application get real-time monitoring and yield forecasting for their solar-enabled homes. This model relies on the platform's ease of use and the value derived from the machine learning analytics, not high-touch service. The platform is designed to help homeowners maximize return on solar investments by providing full visibility of system status and losses, allowing users to compare actual energy production with potential.

Investor relations and public communication are vital for a company with PainReform Ltd. (PRFX)'s capital structure. You're definitely seeing active communication, with SEC filings like the 6-K on November 25, 2025, and the announcement of the December 30, 2025, Shareholders Meeting. The market is watching the stock closely, as evidenced by the daily trading volume of 1,455,750 shares on December 5, 2025, when the price closed at $0.96 after a -5.82% change. The company's financial footing, with Total Shareholder Equity at $8.4M and a debt-to-equity ratio of 0% (Total Debt $0.0), is a key data point shared to support capital market confidence.

Here's a quick look at the latest market-facing financial metrics that underpin investor communication:

Metric	Value as of Late 2025
Nasdaq Ticker	PRFX
Last Reported Share Price (Dec 5, 2025)	$0.96
Daily Volume (Dec 5, 2025)	1,455,750
Market Capitalization	$1.77M
Total Shareholder Equity	$8.4M
Total Debt	$0.0
Short-Term Assets	$3.9M

The relationship strategy is clearly bifurcated:

• Direct engagement with KOLs/surgeons for clinical validation.
• Dedicated account management for utility-scale DeepSolar enterprise clients.
• Self-service model for MyDeepSolar consumer app users.
• Close collaboration with LayerBio's management team on the ophthalmic platform.
• Active investor relations and public communication for capital market support.

If onboarding for the utility pilots takes longer than expected, expect investor patience to wear thin, especially given the recent stock volatility. Finance: draft the Q4 2025 cash burn projection by next Tuesday.

PainReform Ltd. (PRFX) - Canvas Business Model: Channels

You're looking at how PainReform Ltd. (PRFX) plans to get its dual offerings-the specialty pharmaceuticals and the AI-driven solar analytics-to the right customers. Given the company's financial position as of mid-2025, with cash around $3.5 million as of June 30, 2025, and a market capitalization around $3.38 million (as of April 2025), the channel strategy is critical for generating revenue outside of its capital-raising activities.

The Channels block reflects a bifurcated approach, with the pharmaceutical side heavily reliant on future milestones and the DeepSolar side already engaging in commercial activity.

Pharmaceutical Channels: PRF-110 and OcuRing™-K

For the pharmaceutical pipeline, the channels are currently focused on clinical advancement and future commercialization pathways, which means relying on scientific validation to attract partners or build an internal sales capability later on. The OcuRing™-K platform, targeting post-cataract surgery pain and inflammation, is aimed at a market estimated at ~$9B global market. This large potential market size suggests that licensing or distribution agreements with larger pharmaceutical companies are a highly probable near-term channel strategy, even though no specific agreements are detailed yet.

• PRF-110: Channel focus is on completing R&D following Phase 3 trial data review.
• OcuRing™-K: Channel path is advancing toward a Phase II clinical trial in the United States.
• Scientific validation is the primary channel driver for both assets.

DeepSolar Channels: Enterprise and Digital Reach

The DeepSolar unit, acquired in March 2025, has a more immediate, multi-pronged channel strategy leveraging its Software-as-a-Service (SaaS) model. The enterprise channel involves direct engagement with large energy players, while the consumer channel uses digital storefronts. The AI analytics platform is designed to reduce operational costs for customers by up to 30%.

• Direct-to-enterprise sales are being tested via pilot programs.
• Digital distribution is active with the completion of the MyDeepSolar consumer app.
• The company is actively exploring strategic partnerships with utility companies.

Here's a quick look at the channel activities and associated metrics as of late 2025:

Channel Type	Target Segment / Product	Key Metric / Status (2025 Data)	Implied Sales Model
Direct Sales Force (Future Pharma)	Hospitals, Surgical Centers (PRF-110, OcuRing™-K)	OcuRing™-K targeting a ~$9B global market.	Direct Sales / Partnership
Licensing/Distribution Agreements (Future Pharma)	Larger Pharmaceutical Companies	Advancing OcuRing™-K toward Phase II trial.	Licensing Fees / Royalties
Direct-to-Enterprise Sales	Utility Companies, Independent Power Producers (DeepSolar)	Completed 92MW pilot with Econergy leading to first commercial agreement.	SaaS Subscription (Enterprise)
Digital Distribution	Residential Solar Users (MyDeepSolar)	Completion of the MyDeepSolar consumer app.	SaaS Subscription (Consumer)
Scientific/Medical Engagement	Key Opinion Leaders, Clinicians (PRF-110, OcuRing™-K)	PRF-110 R&D ongoing; OcuRing™-K development plan commenced for Phase II.	Milestone Payments / Data Dissemination

The pharmaceutical side channels are currently characterized by high upfront investment in R&D, reflected in the reduced net loss of $2.3M for the first six months of 2025 compared to the prior-year period. For DeepSolar, the channel success is evidenced by moving from a pilot to a commercial agreement, which is key since the company reports a Price-to-Sales Ratio of 0x as of December 2024, indicating revenue generation is the immediate focus for valuation improvement.

PainReform Ltd. (PRFX) - Canvas Business Model: Customer Segments

You're looking at the distinct groups PainReform Ltd. (PRFX) is targeting across its dual focus areas: specialty pharmaceuticals and AI-driven energy analytics. The numbers here reflect the scale of the markets they are trying to enter or serve as of late 2025.

Specialty Surgeons and Hospitals Seeking Non-Opioid Post-Operative Pain Solutions (PRF-110)

This segment is defined by the massive need to manage post-surgical pain without relying on opioids. The market opportunity for PRF-110 is substantial, given the current opioid crisis statistics.

• Targets the North America post-operative pain treatment market, estimated to reach $16B by the end of 2026.
• Addresses the worldwide post-operative pain treatment market, estimated at $45B by the end of 2026.
• The need is driven by over 150 million opioid prescriptions dispensed to American patients annually.
• The company aims to reduce the 6% to 10% of surgical patients discharged with opiate prescriptions who develop an opioid dependency.

Ophthalmologists and Cataract Surgery Centers (for OcuRing™-K)

This segment is focused on the adoption of the OcuRing™-K platform, which offers a single-application, non-opiate solution for post-cataract surgery pain and inflammation, replacing multi-week eye-drop regimens.

Here's a breakdown of the procedure volume PainReform Ltd. is targeting with this technology:

Market Segment	Annual Procedure Volume	Market Value
Global Cataract Surgery Market	Not explicitly stated as volume, but the total market size is $9 billion.	$9 billion global annual procedure volume.
United States Cataract Surgeries	Approximately 4.5 million surgeries performed annually.	Valued at over $3 billion in the US alone.
Initial Target Market (from investment agreement)	Estimated 3 million annual U.S. procedures.	Not explicitly stated as value.

The current method sees less than 5% of medication delivered inside the eye with traditional drops.

Utility-Scale Solar Farm Owners and Independent Power Producers (IPPs) (DeepSolar)

This group represents commercial clients for PainReform Ltd.'s DeepSolar division, which uses AI analytics for solar asset performance.

• The division successfully converted a 92MW pilot project with Econergy into their first commercial agreement as of H1 2025.
• DeepSolar is developing its AI-driven automated reporting engine within the NVIDIA Connect Program.

Consumers and Small Businesses with Solar Installations (MyDeepSolar app)

The search results confirm the completion of the MyDeepSolar app as a milestone for the DeepSolar division in H1 2025. Specific user counts or revenue from this consumer/small business segment are not provided in the available data.

Potential Pharmaceutical Partners for Regional or Global Licensing

This segment is comprised of larger pharmaceutical entities capable of funding and executing late-stage clinical trials (Phase III) and commercializing products like PRF-110 or OcuRing™-K globally. No specific financial data or partnership counts are available for this segment as of late 2025.

PainReform Ltd. (PRFX) - Canvas Business Model: Cost Structure

You're looking at the cost side of the PainReform Ltd. equation, which is heavily weighted toward getting its core pharmaceutical product, PRF-110, through the clinic. Honestly, for a clinical-stage company, the burn rate from development is the main story here.

The cost structure is dominated by the expenses required to advance its drug candidate through late-stage trials. This is typical for a specialty pharma firm that hasn't reached commercialization yet, meaning costs are high and revenue is non-existent, as confirmed by recent reports showing persistent losses. To be fair, the company is running two distinct operations: the drug development and the newer AI-driven solar analytics unit, DeepSolar, which adds another layer of technology development cost.

Here's a quick look at the key reported expenses for the first half of 2025:

Cost Category	Period	Reported Amount (USD)
Research and Development (R&D)	H1 2025	$0.3 million
General and Administrative (G&A)	H1 2025	$1.9 million

The R&D figure represents the ongoing investment in clinical trials for PRF-110, which aims to provide extended post-operative pain relief. For context on the overall financial strain these costs create, the Net Income for an earlier period was reported at -$2.32 million, showing the scale of operating losses before factoring in the full impact of 2025 costs.

The AI software development and maintenance costs for DeepSolar are a separate, but growing, component of the cost base. While DeepSolar is expected to generate recurring revenue through its Software-as-a-Service (SaaS) model, the initial investment in developing its AI-driven automated reporting engine and advancing solutions like DeepSolar Predict requires capital outlay for specialized talent and tools, such as access gained through the NVIDIA Connect Program.

Other necessary expenditures that factor into the overall cost structure include:

• Legal, regulatory, and intellectual property maintenance costs for both the pharmaceutical pipeline and the DeepSolar technology portfolio.
• Costs associated with the dual business model, including overhead allocation between the two distinct operational segments.

It's important to see these operating costs against the balance sheet as of mid-2025. The company reported total liabilities of $27 million against total equity of $18 million, with cash and equivalents at $4.26 million. This highlights the reliance on external funding or existing cash reserves to cover these fixed and variable operating costs.

On the DeepSolar side, while it is a cost center for PainReform Ltd. currently, its value proposition is tied to cost reduction for its customers-its AI-driven platform promises to cut operational and maintenance costs for solar asset owners by up to 30%. Finance: draft 13-week cash view by Friday.

PainReform Ltd. (PRFX) - Canvas Business Model: Revenue Streams

You're looking at the revenue picture for PainReform Ltd. (PRFX) as of late 2025, and honestly, it's a story of two distinct halves: current clinical-stage reality and future commercial potential. Right now, the numbers tell a clear story about the pharmaceutical side.

Currently zero revenue from product sales (clinical-stage company).

• As of the latest financial disclosure, PainReform reported 0.0 of revenue.
• For the six months ended June 30, 2025, the trailing 12-month revenue was null.
• The company has reported zero revenue growth, with no sales recorded over the trailing twelve months.
• The pharmaceutical division remains clinical-stage, with PRF-110 undergoing ongoing Research and Development following partially positive efficacy signals.
• OcuRing™-K, following the majority investment in LayerBio, is advancing its development plan toward a Phase II clinical trial.

Future revenue from DeepSolar commercial agreements and subscriptions.

The DeepSolar division is where PainReform Ltd. is actively generating commercial traction. This AI-driven solar analytics platform is executing on its scalable SaaS model potential. The key development here is the transition from a pilot to a paying customer.

• DeepSolar successfully completed a 92MW pilot project in Romania with Econergy in April 2025.
• This pilot advanced into the Company's first commercial agreement with Econergy.
• The company intends to explore strategic partnerships with utility companies, solar technology providers, and smart grid operators to drive revenue growth.

Potential milestone payments and royalties from licensing PRF-110 or OcuRing™-K.

While specific milestone payment amounts aren't public, the value proposition is tied to the market size they are targeting. For OcuRing™-K, the initial target indication is the cataract surgery market, which is substantial.

• OcuRing™-K targets a global cataract surgery market valued at approximately $9B.
• The US cataract surgery market involves roughly 4.5M annual surgeries.
• Success in the US could unlock a high-volume reimbursable market and enable expansion to additional ophthalmic indications.

Future direct product sales of PRF-110 and OcuRing™-K post-approval.

This stream is entirely dependent on successful clinical progression and regulatory clearance. The current focus is on advancing the pipeline, not on current sales figures for these products.

Equity financing and capital raises to fund operations.

Since product sales are currently zero, operations are funded by capital raises and managing existing cash reserves. Here's a quick look at the funding and cash position as of mid-to-late 2025, based on the latest available figures.

Financial Metric	Amount (Millions USD)	Period End Date	Source
Cash and Cash Equivalents	$3.5	June 30, 2025
Positive Working Capital	$1.5	June 30, 2025
Net Loss (Six Months)	$2.3	June 30, 2025
Net Loss (Full Year)	$14.6	December 31, 2024
Public Offering Proceeds (Recent)	$0.9	2025 (via ATM program)
Public Offering Proceeds (Prior)	$4.0	April 2024

The company is definitely burning cash while advancing its pipeline, as shown by the net loss figures. Finance: draft 13-week cash view by Friday.